Cost of care associated with utilization of telehealth in clinical trials
Incorporating telehealth in gynecologic cancer clinical trials during the COVID-19 pandemic did not increase cost of care and may be a mechanism for decentralizing clinical trials, reducing barriers to trial participation, and improving the value of cancer care.
Authors
- Nathanael Koelper (ORCID: https://orcid.org/0000-0002-3977-6856)
- Simon J. Gunter (ORCID: https://orcid.org/0000-0001-7125-9296)
- Emily Gleason (ORCID: https://orcid.org/0000-0003-4789-995X)
- Leslie Andriani (ORCID: https://orcid.org/0000-0002-1435-9722)
- Heidi S. Harvie (ORCID: https://orcid.org/0000-0002-6675-9808)
- Elizabeth Tubridy (ORCID: https://orcid.org/0000-0002-1148-5221)
- Emily Ko (ORCID: https://orcid.org/0000-0002-9438-1566)
- Destiny Uwawuike
Institutions
- Harvard University (US)
- Danbury Hospital (US)
- Pennsylvania Hospital (US)
- University of the Arts (US)
- University of Pennsylvania Health System (US)
- Abramson Cancer Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1016/j.gore.2024.101523
- Primary Topic
- Telemedicine and Telehealth Implementation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Pennsylvania
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute